Access
To read this story in full you will need to login or make a payment (see right).
News
Nature 440, 855-856 (13 April 2006) | doi:10.1038/440855a; Published online 12 April 2006
Open Innovation Challenges
- More Challenges
- Powered by:
nature jobs
PhD - Helmholtz International Graduate School for Infection Research
- Helmholtz-Zentrum fur Infektionsforschung
- Braunschweig Germany
Dermapathologist
- Indiana University School of Medicine
- Indiana, USA
Can super-antibody drugs be tamed?
Abstract
As it becomes clear that the London clinical trial disaster was indeed the fault of the drug itself, Michael Hopkin looks at what went wrong, and whether there is any future for 'superagonist' antibody therapies.
There was no warning from animal tests, but last month the experimental antibody drug TGN1412 put six British men in intensive care. The resulting investigation ruled out any failure of experimental and regulatory procedures — a relief for those involved, but a damaging blow for the field.
To read this story in full you will need to login or make a payment (see right).
